一线帕西瑞肽治疗能治愈肢端肥大症吗？ - Suppr

Acromegaly can be cured by first-line pasireotide treatment?

作者信息

Chiloiro Sabrina, Giampietro Antonella, Bianchi Antonio, Tartaglione Tommaso, Bima Chiara, Vita Maria Gabriella, Spinello Maurizio, Pontecorvi Alfredo, De Marinis Laura

机构信息

Pituitary Unit, Fondazione Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy.

Department of Radiology, Istituto Dermopatico dell'Immacolata, Rome and Università Cattolica del Sacro Cuore, Rome, Italy.

出版信息

Endocrine. 2019 Apr;64(1):196-199. doi: 10.1007/s12020-019-01874-4. Epub 2019 Feb 23.

DOI:10.1007/s12020-019-01874-4

PMID:30798431

Abstract

摘要

相似文献

Acromegaly can be cured by first-line pasireotide treatment?

Endocrine. 2019 Apr;64(1):196-199. doi: 10.1007/s12020-019-01874-4. Epub 2019 Feb 23.

Evolution of (18)FDG pituitary uptake after medical control of acromegaly.

Pituitary. 2014 Jun;17(3):296-7. doi: 10.1007/s11102-013-0513-1.

Potential antitumour activity of pasireotide on pituitary tumours in acromegaly.

Lancet Diabetes Endocrinol. 2019 Jun;7(6):425-426. doi: 10.1016/S2213-8587(19)30113-5. Epub 2019 Apr 4.

Pasireotide in acromegaly by aggressive tumors, description of four clinical cases. Towards a personalized medicine.

Endocrinol Diabetes Nutr (Engl Ed). 2018 Feb;65(2):130-132. doi: 10.1016/j.endinu.2017.12.001. Epub 2018 Jan 20.

Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study.

J Clin Endocrinol Metab. 2019 Nov 1;104(11):5478-5482. doi: 10.1210/jc.2019-00825.

[Outcome of somatostatin analogue treatment in acromegaly].

Orv Hetil. 2009 Aug 2;150(31):1457-62. doi: 10.1556/OH.2009.28688.

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.

Pituitary. 2014 Apr;17(2):132-40. doi: 10.1007/s11102-013-0478-0.

Pituitary gangliocytoma-adenoma presenting with acromegaly: response to treatment.

Arch Intern Med. 2001 Apr 9;161(7):1010-1. doi: 10.1001/archinte.161.7.1010.

[Difficulties of treating acromegaly in the light of 12 years of experience].

Orv Hetil. 2024 Oct 6;165(40):1587-1593. doi: 10.1556/650.2024.33156.

111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.

J Endocrinol Invest. 1997 Jul-Aug;20(7):424-8. doi: 10.1007/BF03347995.

引用本文的文献

Pasireotide as first line medical therapy for selected patients with acromegaly.

Pituitary. 2025 Apr 11;28(3):48. doi: 10.1007/s11102-025-01514-3.

Long-term Remission in Functioning Pituitary Adenomas after Medical Therapy Withdrawal: A Chance for Cushing's Disease.

Endocr Metab Immune Disord Drug Targets. 2025;25(10):824-833. doi: 10.2174/0118715303328077240719055819.

Successful medical management of a pituitary macroadenoma with features of resistant acromegaly and hyperprolactinemia using pasireotide.

Qatar Med J. 2024 Mar 14;2024(1):17. doi: 10.5339/qmj.2024.17. eCollection 2024.

Systemic comorbidities of acromegaly in real-life experience: which difference among young and elderly patients?

Endocrine. 2023 Apr;80(1):142-151. doi: 10.1007/s12020-022-03261-y. Epub 2022 Nov 29.

Somatostatin receptors in normal and acromegalic somatotroph cells: the U-turn of the clinician to immunohistochemistry report - a review.

Rom J Morphol Embryol. 2020 Apr-Jun;61(2):353-359. doi: 10.47162/RJME.61.2.05.

Acromegaly in the elderly patients.

Endocrine. 2020 Apr;68(1):16-31. doi: 10.1007/s12020-020-02206-7. Epub 2020 Feb 14.

本文引用的文献

Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study.

Endocr J. 2017 Jul 28;64(7):735-747. doi: 10.1507/endocrj.EJ16-0624. Epub 2017 Jul 8.

Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control.

Hormones (Athens). 2017 Jan;16(1):84-91. doi: 10.14310/horm.2002.1722.

Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study.

Endocrine. 2017 Jan;55(1):247-255. doi: 10.1007/s12020-016-1182-4. Epub 2016 Nov 28.

Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly.

J Formos Med Assoc. 2016 Jun;115(6):475-80. doi: 10.1016/j.jfma.2016.02.003. Epub 2016 Apr 23.

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.

BMC Endocr Disord. 2016 Apr 2;16:16. doi: 10.1186/s12902-016-0096-8.

Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.

Eur J Endocrinol. 2016 Feb;174(2):241-50. doi: 10.1530/EJE-15-0832. Epub 2015 Nov 19.

Management of endocrine disease: pituitary tumour apoplexy.

Eur J Endocrinol. 2015 May;172(5):R179-90. doi: 10.1530/EJE-14-0794. Epub 2014 Dec 1.

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.

Lancet Diabetes Endocrinol. 2014 Nov;2(11):875-84. doi: 10.1016/S2213-8587(14)70169-X. Epub 2014 Sep 24.

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.

Pituitary. 2015 Jun;18(3):385-94. doi: 10.1007/s11102-014-0585-6.

Expert consensus document: A consensus on the medical treatment of acromegaly.

Nat Rev Endocrinol. 2014 Apr;10(4):243-8. doi: 10.1038/nrendo.2014.21. Epub 2014 Feb 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Acromegaly can be cured by first-line pasireotide treatment?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献